Pharmaceutical Technology
NOVEMBER 16, 2022
Affini-T’s platform can choose and engineer the correct immune cells to create a lasting and coordinated immune response in the immunosuppressive tumour microenvironment. To act on oncogenic driver mutations, Affini-T is using engineered T-cell therapies with synthetic biology and gene editing enhancements.
Camargo
JULY 27, 2021
Gene therapy is a new therapeutic approach in which genes are used to treat or prevent diseases. It is a comprehensive term which encompasses a large variety of therapy products including viral and bacterial vectors, plasmid DNA, human gene editing technology, and patient-specific cellular gene therapy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 11, 2021
That is an approach that has been tried in other groups, but so far efforts have been impeded by difficulties in producing enough cells of sufficient quality and protecting them from the patient’s immune response. That implantable technology was at the heart of the Semma acquisition.
XTalks
OCTOBER 12, 2021
The vaccine was tested in rats and showed strong, immediate and long-lasting immune responses to confer protection against the disease. is an autoantigen, which means it is an endogenous antigen that triggers an immune response in the body. as a potential trigger for rheumatoid arthritis.
BioTech 365
OCTOBER 22, 2020
-Proof-of-concept achieved for VY-UC to engineer donor cells without the complexities of gene-editing -Novel platform abrogates cellular immune response and obviates the need for immunosuppressive drugs TAMPA, Fla. & & STOCKHOLM–(BUSINESS WIRE)–#celltherapy–Vycellix, Inc.,
XTalks
NOVEMBER 30, 2023
These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV. In 2021, the FDA granted approval to San Francisco-based Excision BioTherapeutics to start trials assessing CRISPR gene editing as a potential treatment for HIV. In November 2023, Hookipa Pharma Inc.,
The Pharma Data
NOVEMBER 16, 2020
The gene edit prevents the virus from performing its normal evasive maneuver: hiding out in nervous system cells in order to elude the immune system. As Pickard explained, one issue is that some candidate vaccines use only a subset of HSV components, or antigens, to try to generate an immune response. MONDAY, Nov.
Expert insights. Personalized for you.
246 
Let's personalize your content